Protagonist Therapeutics Inc (NASDAQ: PTGX) — Healthcare · Share Price, Chart & Market Data
About: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $100.00 (-2.55%)
PTGXProtagonist Therapeutics Inc
Loading watchlist status…
Trade PTGX now
Protagonist Therapeutics Inc share price
PTGX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 7:33 am GMT+0
PTGX price performance
-5.186%
5D
-0.388%
1M
14.705%
YTD
122.965%
1Y
PTGX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 7:33 am GMT+0
PTGX details
PTGX Market Signals